{rfName}
Di

Indexed in

License and Use

Icono OpenAccess

Citations

5

Altmetrics

Analysis of institutional authors

Crans, Rene A JAuthorDierssen, MaraAuthor

Share

July 31, 2025
Publications
>
Article
Sí

Disease-specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease

Publicated to: Alzheimers & Dementia. 21 (6): e70262- - 2025-06-01 21(6), DOI: 10.1002/alz.70262

Authors:

Fructuoso, M; Vermeiren, Y; Boluda, S; Stimmer, L; Crans, RAJ; Xicota, L; Eisel, U; Casan, NO; Bun, P; Duyckaerts, C; Delabar, JM; Strydom, A; Van Dam, D; Dierssen, M; De Deyn, P; Potier, MC
[+]

Affiliations

Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Carrer Doctor Aiguader, Barcelona, Spain - Author
Hop La Pitie Salpetriere, AP HP, Lab Neuropathol R Escourolle, Paris, France - Author
Hop La Pitie Salpetriere, Paris Brain Inst, 47 BD Hop, F-75013 Paris, France - Author
Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Forens & Neurodev Sci, London, England - Author
Sorbonne Univ, Hop Pitie Salpetriere, Paris Brain Inst, Inst Cerveau,ICM,CNRS,INSERM, Paris, France - Author
Univ Antwerp, Dept Biomed Sci, Expt Neurobiol Unit, Lab Neurochem & Behav, Antwerp, Belgium - Author
Univ Groningen, Groningen Inst Evolutionary Life Sci, Dept Mol Neurobiol, Fac Sci & Engn, Groningen, Netherlands - Author
Univ Groningen, Univ Med Ctr Groningen, Alzheimer Ctr, Gronongen, Netherlands - Author
Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Gronongen, Netherlands - Author
Univ Paris Cite, Inst Psychiat & Neurosci Paris IPNP, INSERM, NeurImag Core Facil,U1266, Paris, France - Author
Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain - Author
Wageningen Univ & Res WUR, Chair Grp Nutr Biol, Div Human Nutr & Hlth, Wageningen, Netherlands - Author
See more

Abstract

INTRODUCTIONThe locus coeruleus (LC), the brain's primary source of noradrenaline (NA), undergoes early neurodegeneration in Parkinson's disease (PD), Alzheimer's diseases (AD), and Down syndrome (DS); however, differences have not been examined in parallel.METHODSPost mortem brains (n = 67) from individuals with AD, DS-AD, and PD without and with dementia (PD-D) and controls were analyzed for amyloid beta (A beta), phosphorylated tau (pTau), alpha-synuclein, endo-lysosomal alterations, biogenic amines, and selective biomarkers.RESULTSLC degeneration correlated with age, peaking in AD and PD-D, while NA and dopaminergic metabolites were significantly reduced only in PD-D. DS-AD, the youngest group, showed the highest A beta and pTau levels but the least noradrenergic neuron loss. We demonstrated for the first time that endosomal alterations were present in AD, lysosomal changes were present in PD-D/DS-AD, and DYRK1A, a key protein from chromosome 21, was elevated only in DS-AD.DISCUSSIONLoss of noradrenergic neurons may occur independently of amyloid and tau pathologies.Highlights We provide the first analysis of neuropathological and biochemical features including biogenic amines of the LC in AD, DS, and PD. Loss of noradrenergic neurons was most severe in AD and PD. Only in DS, levels of DYRK1A - a kinase encoded on chromosome 21 and implicated in neurodegenerative processes - were elevated and negatively correlated to biogenic amine levels. Although individuals with DS having AD were the youngest group, they had the highest levels of amyloid and tau pathologies, but less noradrenergic neurons loss compared to other disease groups.
[+]

Keywords

Alpha-synucleinAmyloid-betaCoeruleusDyrk1aEndo-lysosomal pathwayLocus coeruleusMild cognitive impairmentNeurodegenerative diseaseNorepinephrineNucleusProteinSystemTaUp-regulation

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Alzheimers & Dementia due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2025, it was in position 6/286, thus managing to position itself as a Q1 (Primer Cuartil), in the category Clinical Neurology. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-03:

  • WoS: 2
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-03:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 10.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 10 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 7.
  • The number of mentions in news outlets: 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Belgium; France; Netherlands; United Kingdom.

[+]

Awards linked to the item

Agence Nationale de la Recherche, Grant/Award Numbers: ANR-17-JPCD-0003, COEN-0002, COEN-4024, ANR-10-AIHU-06; Agencia Estatal de Investigacion, Grant/Award Numbers: PID2022-141900OB-I00, AC170006,ZonMW 733051072; MRC, Grant/Award Number: MR/R024901/1; Spanish Ministry of Science and Innovation, Grant/Award Number: CEX2020-001049-S,MCIN/AEI/10.13039/501100011033; Generalitat de Catalunya, Grant/Award Number: CERCA; Fondation Jerpme Lejeune, Fondation Sisley-d'Ornano; EMBL Partnership
[+]